GlassScriptPhysician profile
Daniel William Sonnenburg
NPI 1538508965
$36,662.78
in general payments reported to CMS, 2019-2025
20 companies · $15K in 2025
The $15K reported for 2025 was more than what 85% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $83.76 · 2021: $316 · 2022: $210 · 2023: $11K · 2024: $9,152 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Consulting Fee: $5,570 · Food and Beverage: $3,511 · Travel and Lodging: $159 · Education: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,600.00 |
| Consulting Fee | $5,570.00 |
| Food and Beverage | $3,510.52 |
| Travel and Lodging | $159.00 |
| Education | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $29,743.81 | 2019-2025 | Lynparza, Truqap, Imfinzi |
| Merck Sharp & Dohme LLC | $3,639.81 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $726.68 | 2023-2025 | Rybrevant, Carvykti, Erleada |
| Eisai INC. | $632.02 | 2019-2025 | |
| Inari Medical, INC. | $549.50 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Pfizer INC. | $476.01 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $329.37 | 2023-2025 | Orgovyx |
| Genzyme Corporation | $209.22 | 2022-2023 | |
| Genmab U.S., INC. | $139.77 | 2021-2024 | Tivdak |
| Tempus Ai, INC | $61.24 | 2024 | |
| Foundation Medicine, INC. | $39.69 | 2020-2023 | Foundationone Cdx |
| Corcept Therapeutics | $28.96 | 2025 | Korlym |
| Immunogen, INC. | $28.53 | 2023 | Elahere |
| Astellas Pharma US INC | $23.35 | 2025 | Padcev |
| Becton, Dickinson and Company | $17.97 | 2023 | Bd Onclarity |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $16.85 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sonnenburg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.